Ge Healthcare Limited

Ge Healthcare As

Hammersmith Imanet Limited

Amersham Plc

Alexander Mark Gibson

Alan Cuthbertson

Bengt Langstrom

Magne Solbakken

Anthony Eamon Storey

Farhad Karimi

Steven Michael Fairway

Lorenzo Williams

Robert James Nairne

Denis Raymond Christophe Bouvet

Clare Louise Jones

Sajinder Kaur Luthra

Frank Brady

Nicolas Lasbistes

Bente E Arbo

Erik Arstad

Duncan George Wynn

Marivi Mendizabal

Philip Duncanson

Nicholas Toby Jeffery

Lynda Jane Brown

Richard Charles Downie Brown

Richard Pither

Nicholas Lasbistes

Vaughan Griffiths

Shirley Elizabeth Pullan

Duncan Wynn

The invention relates to a process for preparation of a compound of formula (I): Ris selected from Calkyl, Calkenyl, and Calkynyl;which comprises:(i) reaction with fluoride, suitably [F]fluoride, of a corresponding compound of formula (II): wherein Ris selected from hydrogen, Calkyl, Chaloalkyl, Caryl, Carylalkyl, &#x2014;(CHCHO)&#x2014;CHwherein q is an integer of from 1 to 10;Ris as defined for the compound of formula (I); andRis a leaving group. Certain novel precursors of formula (II) and radiopharmaceutical kits containing such precursors are also claimed.

Fluorination process

The Invention relates to conjugates of formula (III) or (IIIa), or a salt thereof, their use as radiopharmaceuticals, processes for their preparation, and synthetic intermediates used in such processes.

Diagnostic compounds

The invention relates to a process for preparation of a compound of formula (I): Ris selected from Calkyl, Calkenyl, and Calkynyl; which comprises: (i) reaction with fluoride, suitably [F]fluoride, of a corresponding compound of formula (II): wherein Ris selected from hydrogen, Calkyl, Chaloalkyl, Caryl, Carylalkyl, &#x2014;(CHCHO)&#x2014;CHwherein q is an integer of from 1 to 10; Ris as defined for the compound of formula (I); and Ris a leaving group. Certain novel precursors of formula (II) and radiopharmaceutical kits containing such precursors are also claimed. 

Fluorination process of anilide derivatives and benzothiazole fluorinate derivatives as in vivo imaging agents

The invention provides a process for the production of anF-labelled tracer which comprises treatment of a solid support-bound precursor of formula (I) SOLID SUPPORT-LINKER-X-TRACER (I) wherein X is a group which promotes nucleophilic substitution at a specific site on the attached TRACER and the TRACER is of formula (A). 

Solid-phase fluorination of benzothiazoles

The invention relates to novel processes for the purification of radiolabelled tracers, using a solid-support bound scavenger group. The general concept being illustrated by the scheme:

Purification methods

The invention relates to conjugates of formula (III) or (IIIa), or a salt thereof, their use as radiopharmaceuticals, processes for their preparation, and synthetic intermediates used in such processes.

A process for the production of anF-labelled tracer which comprises treatment of a solid support-bound precursor of formula (I): SOLID SUPPORT-LINKER-SO&#x2014;O-TRACER (I) withF&#x2014; to produce the labelled tracer of formula (II) 

[object Object]

The present invention relates to P or P-labelled bisphosphonates as radiotherapeutic radiopharmaceuticals. The P- or P-labelled bisphosphonates, which are chemically identical to the unlabelled agent, are expected to target the lesion site in an identical manner, but also deliver a significant radiocytotoxic effect to the surrounding cells. This should result, given the favorable energetics of the &bgr; particle emission from the P nuclide, in a loss of proliferative capacity of cells associated with the tumor lesion. The relative stability and in vivo localisation of bisphosphonates makes them good candidates as P/ P delivery vehicles.

Radiolabelled bisphosphonates and method

Growing community of inventors

Amersham, United Kingdom

Alexander Mark Gibson